Skip to main content
. 2019 Aug 1;3(15):2307–2311. doi: 10.1182/bloodadvances.2019000306

Figure 1.

Figure 1.

Association between DTAS mutations and hematologic recovery following induction chemotherapy in AML patients. Cumulative proportion of patients with platelet and neutrophil recovery in those with DNMT3A (A), TET2 (B), ASXL1 (C), and SRSF2 (D) mutations compared with those without any DTAS mutations. The P values were calculated using the log-rank test.